Abstract
By assessing how drug/new chemical entity (NCE) cytotoxicity is affected when their metabolic pathways are inhibited or activated, the metabolic pathways that activate versus detoxify drugs/NCEs can be identified. Reactive metabolites contributing to cytotoxicity can also be identified. In the following, the drug metabolizing enzyme inhibitors and activators used in vitro with freshly isolated rat hepatocytes for the accelerated cytotoxicity mechanism screening (ACMS) of drugs/NCEs (a technique used in our laboratory) are reviewed and, this technique is useful for determining in vivo rat hepatotoxicity mechanisms. The enzyme inhibitors/activators have been chosen on the basis of their selectivity, modulator effectiveness, and their lack of toxicity. The use of these inhibitors/activators with human hepatocytes or subcellular fractions for assessing human hepatotoxicity mechanisms is also reviewed.
Keywords: cytochrome p-450, hepatotoxicity, glucuronosyltransferase, arylamine n-acetyltransferase, sulfotransferases, glutathione transferase, coenzyme a-transferases, enzyme Inhibitors
Current Drug Metabolism
Title: Accelerated Cytotoxicity Mechanism Screening Using Drug Metabolising Enzyme Modulators
Volume: 6 Issue: 2
Author(s): P. J. O'Brien and A. G. Siraki
Affiliation:
Keywords: cytochrome p-450, hepatotoxicity, glucuronosyltransferase, arylamine n-acetyltransferase, sulfotransferases, glutathione transferase, coenzyme a-transferases, enzyme Inhibitors
Abstract: By assessing how drug/new chemical entity (NCE) cytotoxicity is affected when their metabolic pathways are inhibited or activated, the metabolic pathways that activate versus detoxify drugs/NCEs can be identified. Reactive metabolites contributing to cytotoxicity can also be identified. In the following, the drug metabolizing enzyme inhibitors and activators used in vitro with freshly isolated rat hepatocytes for the accelerated cytotoxicity mechanism screening (ACMS) of drugs/NCEs (a technique used in our laboratory) are reviewed and, this technique is useful for determining in vivo rat hepatotoxicity mechanisms. The enzyme inhibitors/activators have been chosen on the basis of their selectivity, modulator effectiveness, and their lack of toxicity. The use of these inhibitors/activators with human hepatocytes or subcellular fractions for assessing human hepatotoxicity mechanisms is also reviewed.
Export Options
About this article
Cite this article as:
O'Brien J. P. and Siraki G. A., Accelerated Cytotoxicity Mechanism Screening Using Drug Metabolising Enzyme Modulators, Current Drug Metabolism 2005; 6 (2) . https://dx.doi.org/10.2174/1389200053586082
DOI https://dx.doi.org/10.2174/1389200053586082 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer Stem Cell Markers in Nasopharyngeal Carcinoma and Its Relevance for Therapy
Current Traditional Medicine RNAi in Clinical Studies
Current Medicinal Chemistry Aurora Kinase Inhibitors in Head and Neck Cancer
Current Topics in Medicinal Chemistry Linking Biosynthetic Gene Clusters to their Metabolites via Pathway- Targeted Molecular Networking
Current Topics in Medicinal Chemistry Current Drug Design of Anti-HIV Agents Through the Inhibition of C-C Chemokine Receptor Type 5
Current Computer-Aided Drug Design Urokinase-type Plasminogen Activator (uPA) and its Receptor (uPAR): Development of Antagonists of uPA / uPAR Interaction and their Effects In Vitro and In Vivo
Current Pharmaceutical Design Identification of WDFY3 Neoantigens as Prognostic Markers in Longterm Survivors of Extrahepatic Cholangiocarcinoma
Current Cancer Drug Targets Resveratrol and Stroke: from Chemistry to Medicine
Current Neurovascular Research Molecular Structural Characteristics of Estrogen Receptor Modulators as Determinants of Estrogen Receptor Selectivity
Mini-Reviews in Medicinal Chemistry Anti-Cancer Activity of Curcumin on Multiple Myeloma
Anti-Cancer Agents in Medicinal Chemistry Across the Universe of K-Ras Mutations in Non-Small-Cell-Lung Cancer
Current Pharmaceutical Design Cytochrome P450 and the Biological Clock in Mammals
Current Drug Metabolism New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets Novel Thiourea Derivatives Bearing Sulfonamide Moiety as Anticancer Agents Through COX-2 Inhibition
Anti-Cancer Agents in Medicinal Chemistry Protein Extracts from Somaclonal Mistletoe (Viscum Album L.) Callus with Increased Tumor Cytotoxic Activity in Vitro
Current Bioactive Compounds Role of EGFR Monoclonal Antibodies in the Management of Non–small Cell Lung Cancer
Current Cancer Drug Targets Polymer-Based Drug Delivery Systems, Development and Pre-Clinical Status
Current Pharmaceutical Design The Role of Folate-supplementation in Depression: A Narrative Review
Current Psychopharmacology Delivery and Application of Dietary Polyphenols to Target Organs, Tissues and Intracellular Organelles
Current Drug Metabolism Meet Our Editorial Board Member
MicroRNA